An Overview of Hepatitis C

Acute Phase Hepatitis C

The first six months after being infected with HCV is called acute phase hepatitis C. After infection, there is a period of 7 to 8 weeks before there is a rise in liver enzymes. HCV antibodies are usually detectable in the blood 3 to 12 weeks after infection. The virus itself is usually detectable in the blood within 1 to 3 weeks after infection.<^1,2

Most people acutely infected with HCV are asymptomatic meaning they do not have any symptoms of disease. However, 25% to 35% of infected people experience a mild illness with vague and nonspecific symptoms.

Fifteen percent to 45% of people infected with HCV appear to clear the virus on their own without developing any secondary condition or result from the infection. Experts believe clearing the virus is at least partially related to the amount of virus in the initial infection.<^3-6  Other factors are also likely to be involved. The process of spontaneous clearance is not well understood, and is an area of active medical research.

If your body does not rid itself of HCV within six months after infection, you are considered to be in the chronic phase of hepatitis C.

Chronic Phase Hepatitis C Infection

The course of chronic phase hepatitis C is usually that of slow disease progression. Most people have no physical signs or symptoms of HCV infection during the first 10 to 20 years after infection. Some have only vague, mild symptoms that come and go without presenting much difficulty.

The rate of disease progression in chronic hepatitis C differs from one person to another. The rate at which a person’s hepatitis C will progress cannot be accurately determined by the liver enzyme levels, viral load, or HCV genotype.^7,8 It has been noted that people with normal liver enzymes and low viral load usually have milder liver disease with lower-grade liver inflammation. However, even these people occasionally develop fibrosis or cirrhosis. The inability to accurately predict disease progression makes it difficult for healthcare providers to identify people who are most likely to benefit from treatment.

Blood-to-Blood Contact

HCV is transmitted from one person to another through blood-to-blood contact. In other words, a person is infected with the hepatitis C virus only if their blood system comes into contact with another person’s HCV-infected blood.⁹ Blood ­to-blood contact occurs in a variety of ways, some very obvious and others you may not have considered.

Examples of blood-to-blood contact that can lead to HCV transmission include:

• receiving blood or blood products prior to 1992
• sharing drug paraphernalia, even once
• being stuck by a used blood needle
• being on kidney dialysis
• having a tattoo or body piercing done in an unsterile environment
• having sexual activity that involves contact with blood
• having a job that exposed you to blood
• sharing personal care items (razors, toothbrushes, nail clippers, etc.) with others
• having been incarcerated
• having been in combat in the military
• having been born prematurely (prior to 1992)

• Hepatitis C is rarely transmitted through sexual intercourse though it does occur. Among the general population, a rate of sexual transmission of 3% or less is considered accurate by most experts.¹⁰ However, increased levels of risk have been reported in association with:^11-12
• multiple sexual partners
• activity that involves blood-to-blood exposure
• the presence of a sexually transmitted infection
• coinfection with HIV have been reported to be important factors in new hepatitis C infections.

CDC states there is no evidence of HCV transmission associated with oral sex.

In general, most experts agree that sexual transmission of HCV through intercourse plays a role in the ongoing spread of the disease, but that this route of transmission is uncommon overall.

If you have any questions about the sexual transmission of hepatitis C, talk with your doctor. All people, regardless of health challenges, are sexual beings and your doctor understands that sexual health is an important component of your overall health.

The hepatitis C family of viruses is divided into groups called genotypes. There are 6 known genotypes and more than 90 subtypes of the hepatitis C virus.¹³ The types are numbered 1 through 6, and the subtypes are labeled a, b, c, and so on, in order of their discovery.

Genotype testing is an important part of standard, western medical care for people with HCV infection who are being counseled about treatment. The reason is that researchers have found certain strains of HCV are more likely to respond to treatment than others are. Further, some strains respond more quickly than others do and require a shorter treatment interval. The majority of Direct acting antiviral therapies being used today are useful on all genotypes (pan-genotypic). However, it is still important to know the genotype and subtype of HCV with which you are infected. If you are infected with one of the strains that is hard to treat, your healthcare provider may advise a longer than normal course of treatment to see if you might eventually respond.

You may hear the term quasispecies in relation to HCV genotype. Quasispecies occur because HCV mutates freely, causing diverse genetic strains in each infected person. The longer you have been infected with HCV, the more likely you are to have a number of quasispecies of HCV in your body. One small study found changes in quasispecies were associated with levels of the liver enzyme ALT during the acute phase of infection. This finding suggests that the formation of quasispecies might be related to the severity of HCV infection.¹⁴ Additional research is need to clarify the role of quasispecies in hepatitis C disease management and treatment.

No studies are available to date showing that genotype influences symptom or disease response to complementary and alternative medicine (CAM) treatments. Further, there are no data to date proving that CAM therapies cure HCV disease (that is, clear the virus from the body).

Information in this section has been updated and adapted from Hepatitis C Choices 4th Edition, Overview of Hepatitis C written by Dr. Robert G. Gish, MD.

1. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology. 1983; 85(2):439-462.
2. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(Suppl 1):9-16.
3. Barrett S, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001 Sep 2001;423-430.
4. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 Suppl 2:3-8.
5. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005; 25(1):7-17.
6. Zhang M, et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2005.
7. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21-28S.
8. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(3 Suppl 1):15-20S.
9. https://www.cdc.gov/hepatitis/hcv/HepatitisCOverview.htm [last Accessed 7/24/2020]
10. Cavalheiro N. Sexual transmission of hepatitis C. Rev Inst Med trop S Paulo [serial online]. 2007; 49(5): 271-277.
11. Wang CC, et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196(10):1474-82.
12. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36(5 Suppl):S99-S105.
13. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34:2259-2266.
14. Yuki N, Hayashi N, et al. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology. 1997;25(2):439-444.